Edap TMS SA (EDAP)
2.52
-0.11
(-4.18%)
USD |
NASDAQ |
Nov 14, 16:00
2.52
0.00 (0.00%)
After-Hours: 20:00
Edap TMS Research and Development Expense (Quarterly): 1.887M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.887M |
| June 30, 2024 | 2.236M |
| March 31, 2024 | 2.247M |
| December 31, 2023 | 2.370M |
| September 30, 2023 | 1.772M |
| June 30, 2023 | 1.829M |
| March 31, 2023 | 1.566M |
| December 31, 2022 | 1.334M |
| September 30, 2022 | 1.371M |
| June 30, 2022 | 1.250M |
| March 31, 2022 | 1.213M |
| December 31, 2021 | 0.6428M |
| September 30, 2021 | 1.254M |
| June 30, 2021 | 1.115M |
| March 31, 2021 | 1.026M |
| December 31, 2020 | 1.714M |
| September 30, 2020 | 1.275M |
| June 30, 2020 | 1.020M |
| March 31, 2020 | 1.150M |
| December 31, 2019 | 0.9346M |
| September 30, 2019 | 0.9852M |
| June 30, 2019 | 1.108M |
| March 31, 2019 | 1.151M |
| December 31, 2018 | 0.3925M |
| September 30, 2018 | 3.651M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.432M |
| March 31, 2018 | 1.228M |
| December 31, 2017 | 1.293M |
| September 30, 2017 | 1.079M |
| June 30, 2017 | 1.066M |
| March 31, 2017 | 0.9545M |
| December 31, 2016 | 1.224M |
| September 30, 2016 | 1.152M |
| June 30, 2016 | 1.002M |
| March 31, 2016 | 0.898M |
| December 31, 2015 | 0.6182M |
| September 30, 2015 | 0.6801M |
| June 30, 2015 | 0.8166M |
| March 31, 2015 | 0.8722M |
| December 31, 2014 | 0.7493M |
| September 30, 2014 | 0.9462M |
| June 30, 2014 | 1.278M |
| March 31, 2014 | 0.9398M |
| December 31, 2013 | 0.7759M |
| September 30, 2013 | 0.5925M |
| June 30, 2013 | 0.8438M |
| March 31, 2013 | 1.230M |
| December 31, 2012 | 0.873M |
| September 30, 2012 | 0.5288M |
| June 30, 2012 | 1.097M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.6428M
Minimum
Dec 2021
2.370M
Maximum
Dec 2023
1.460M
Average
1.304M
Median
Research and Development Expense (Quarterly) Benchmarks
| Genfit SA | -- |
| Cellectis SA | 23.83M |
| Adaptimmune Therapeutics PLC | 40.45M |
| Akari Therapeutics PLC | 3.314M |
| Biodexa Pharmaceuticals PLC | -- |